Abstract 5383
Background
Cancer survivorship is increasing yet cancer treatment can cause de-conditioning and reduce physical capacity. Consequently there is a need to identify interventions which can improve health. This study investigated the impact of a personalised self-management programme on the physical and psychological health of cancer survivors with lifestyle related health risks.
Methods
For the purpose of this research the Moving on Programme was developed which is an intervention for cancer survivors to self-manage lifestyle. A randomised control pilot trial was conducted on 123 cancer survivors with a BMI > 25. Participants were randomly assigned to the control (n = 61) or intervention (n = 62) groups. The intervention group attended the Moving on Programme and engaged in personalised goal-setting to incrementally increase physical activity and made dietary changes. Participants in the control group received only brief standard advice. Objective measures of health behaviour were collected via Fitbit. Data on anthropometric, physiological, dietary behaviour and psychological measures were collected on all participants at baseline, three and six months. A sample of participants were interviewed (n = 13) to examine acceptability of the intervention.
Results
Overall, the results demonstrate a positive effect of the Moving on Programme. There was a significant reduction in BMI observed within the intervention group (p = 0.05) in the first three months. Positive participant outcomes also included improvement in physical and psychological wellbeing, and social functioning with reduced fatigue. Qualitative data demonstrated the acceptability of the intervention and participants identified that the Moving on Programme fulfils a deficit that exists in cancer survivorship and rehabilitation.
Conclusions
The Moving on Programme designed for this study, demonstrated physical and psychological benefits to participants. The use of behaviour change techniques and mobile technology was used effectively as an acceptable intervention that supports weight loss, promotes healthier behaviours and improves wellbeing in cancer survivors.
Clinical trial identification
ISRCTN18676721 https://doi.org/10.1186/ISRCTN18676721.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Irish Cancer Society.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3212 - Multigene panel testing results for hereditary breast cancer in 1325 individuals: implications for gene selection and considerations for guidelines.
Presenter: Georgios Tsaousis
Session: Poster Display session 3
Resources:
Abstract
2591 - PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
Presenter: Julia Quintanilha
Session: Poster Display session 3
Resources:
Abstract
4377 - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): a retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials.
Presenter: Nuria Chic
Session: Poster Display session 3
Resources:
Abstract
3439 - Early on-treatment vs pre-treatment tumor transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer
Presenter: Sonia Pernas
Session: Poster Display session 3
Resources:
Abstract
2512 - AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)
Presenter: Claudia Cardone
Session: Poster Display session 3
Resources:
Abstract
4061 - Prevalence of EGFR mutations and its correlation with Egyptian patients’ human kinetics (PEEK Study)
Presenter: Adel Ibrahim
Session: Poster Display session 3
Resources:
Abstract
2547 - Evaluation of tumor microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)
Presenter: Sergio Rutella
Session: Poster Display session 3
Resources:
Abstract
4671 - Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt).
Presenter: Benoit Rousseau
Session: Poster Display session 3
Resources:
Abstract
3862 - Tumor mutation burden and microsatellite instability in colorectal cancer
Presenter: Francesca Fenizia
Session: Poster Display session 3
Resources:
Abstract
4614 - Predictors of Response to Checkpoint Inhibitors in Naïve and Ipilimumab-Refractory Melanoma
Presenter: Domenico Mallardo
Session: Poster Display session 3
Resources:
Abstract